Paccaud J P, Schifferli J A, Baggiolini M
Division of Nephrology, Centre Médical Universitaire, Geneva, Switzerland.
Biochem Biophys Res Commun. 1990 Jan 15;166(1):187-92. doi: 10.1016/0006-291x(90)91929-m.
The effect of the neutrophil-activating peptide NAP-1/IL-8 on the expression of complement receptor type 1 (CR1) in human neutrophils was studied. NAP-1/IL-8 enhanced CR1 expression at concentrations between 10(-10) and 10(-8) M. The maximum increase with respect to unstimulated control cells was on average 2.3 fold. The effect was rapid: Half-maximum enhancement was obtained in 4 min and the plateau was reached in 15 min. The chemotactic peptide fMLP, tested for comparison, was effective between 10(-9) and 10(-7) M, showed a similar time course and a somewhat higher maximum effect (2.8 fold increase). The effect of NAP-1/IL-8 was prevented by pretreatment of the cells with B.pertussis toxin and desensitization was observed following restimulation. Stimulus combination experiments suggested that NAP-1/IL-8 mobilizes the same or a similar intracellular pool of CR1 receptors as fMLP or C5a.
研究了中性粒细胞激活肽NAP-1/IL-8对人中性粒细胞中补体受体1（CR1）表达的影响。NAP-1/IL-8在10^(-10)至10^(-8)M的浓度范围内增强了CR1的表达。相对于未刺激的对照细胞，最大增加平均为2.3倍。这种作用迅速：在4分钟内获得最大增强的一半，15分钟达到平台期。作为对照测试的趋化肽fMLP在10^(-9)至10^(-7)M之间有效，显示出相似的时间进程和略高的最大效应（增加2.8倍）。用百日咳毒素预处理细胞可阻止NAP-1/IL-8的作用，再次刺激后观察到脱敏现象。刺激组合实验表明，NAP-1/IL-8动员的CR1受体细胞内池与fMLP或C5a相同或相似。
